Idx’s first product, IDx-DR, is an AI diagnostic system that analyzes images of the retina to detect diabetic retinopathy and enables non–eye-care clinicians to screen patients without specialist interpretation. The company received FDA clearance for IDx-DR in April, and the system was put into clinical use at University of Iowa Health Care in June. Idx emphasizes an autonomous, biomarker-based approach rather than a black box model, which the company says has allowed real-world execution. This week Idx announced a $33 million tranche of funding led by 8VC, with participation from Optum Ventures, Alpha Edison and Heritage Provider Network, taking total funding past $54 million. The company expects the investment to accelerate adoption of IDx-DR for the roughly 30 million Americans who need diabetic retinopathy screening annually. Idx is also developing additional AI diagnostic systems targeting glaucoma, stroke risk, Alzheimer’s, macular degeneration and cardiovascular disease.

Total raised

$33M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2018